Biomarker-driven precision oncology revolutionizes cancer treatment by targeting unique genetic identifiers within tumors, thus fostering highly tailored therapies. This targeted approach significantly enhances patient outcomes through more effective treatments. Our extensive portfolio in this space demonstrates our dedication to such groundbreaking advancements, with numerous programs aimed at harnessing the potential of biomarkers for precise therapy. Among these, our potentially first-in-class KIF18A inhibitor stands as a testament to our commitment, symbolizing our ambition to pioneer the field of precision oncology and drive significant breakthroughs in cancer care.

Artificial Intelligence (AI) is rapidly transforming the field of drug discovery, and we're at the forefront of leveraging this innovative technology. Our AI-guided approach spans across several key stages of drug development, from initial target identification, through drug discovery, to biomarker detection. With AI, we can process vast amounts of biomedical data to identify new therapeutic targets swiftly and accurately, which could potentially speed up the traditionally lengthy process of drug discovery. Furthermore, AI algorithms enable us to predict the efficacy of drug candidates, optimizing our discovery pipeline and increasing our success rates. Also, in the realm of biomarker discovery, AI provides us with a robust tool to unearth novel markers, enhancing our precision oncology efforts and offering a more personalized approach to cancer treatment. Our embrace of AI-guided drug discovery underscores our commitment to deploying cutting-edge technology in our relentless pursuit of innovative cancer therapies.